SER - serinatherapeutics.com Revenue Growth Rate YoY (Last Twelve Months)

Brandmark of Serina Therapeutics, Inc. (SER)

Proprietary brain drug delivery technology provides Serina Therapeutics, Inc. (SER) with exclusivity in neurology. Capitalization relies on grants and partnership payments, while long-term licensing will determine future cash flow. Structural flexibility is maintained through external manufacturing outsourcing. The LTM sales growth YoY metric visualizes actual turnover, where 0.00 serves as the current parameter value.

Serina (SER) Sales Growth YoY (Last Twelve Months): for the period 11/23/2025 - 11/19/2026

Summary analytical data breakdowns for Serina Therapeutics (SER)

- market value and analyst target forecast:
Summary company analytics:SER Serina Pharma
Manufactured product of serinatherapeutics.com

The operational efficiency of Serina Therapeutics, Inc. (SER) is reflected through the relative year-over-year revenue dynamics (LTM). This indicator captures the rolling twelve-month revenue growth to verify the sustainability of the business model. The calculation allows for the determination of the actual resilience of cash flows during industry downturns. For a company developing the POZ polymer platform, this metric confirms the commercial potential of its Parkinson's disease therapy. A stable trend indicates high asset quality.